Nuria Alvarez

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

New insights into thiopurine toxicity: The contribution of rare XDH variants to myelotoxicity.

New insights into thiopurine toxicity: The contribution of rare XDH variants to myelotoxicity.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: June 05, 2025

Novel risk loci for COVID-19 hospitalization among admixed American populations.

Novel risk loci for COVID-19 hospitalization among admixed American populations.

Journal: eLife

Published: October 03, 2024

Author Correction: Exome sequencing identifies breast cancer susceptibility genes and defines the contribution of coding variants to breast cancer risk.

Author Correction: Exome sequencing identifies breast cancer susceptibility genes and defines the contribution of coding variants to breast cancer risk.

Journal: Nature genetics

Published: September 26, 2023

A Comprehensive Analysis of 21 Actionable Pharmacogenes in the Spanish Population: From Genetic Characterisation to Clinical Impact.

A Comprehensive Analysis of 21 Actionable Pharmacogenes in the Spanish Population: From Genetic Characterisation to Clinical Impact.

Journal: Pharmaceutics

Published: March 10, 2023

Exome sequencing identifies breast cancer susceptibility genes and defines the contribution of coding variants to breast cancer risk.

Exome sequencing identifies breast cancer susceptibility genes and defines the contribution of coding variants to breast cancer risk.

Journal: Nature genetics

Published: June 17, 2022

Novel genes and sex differences in COVID-19 severity.

Novel genes and sex differences in COVID-19 severity.

Journal: Human molecular genetics

Published: February 15, 2022

POLRMT as a Novel Susceptibility Gene for Cardiotoxicity in Epirubicin Treatment of Breast Cancer Patients.

POLRMT as a Novel Susceptibility Gene for Cardiotoxicity in Epirubicin Treatment of Breast Cancer Patients.

Journal: Pharmaceutics

Published: October 15, 2021

A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial.

A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: November 16, 2020

Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation.

Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation.

Journal: Nature communications

Published: April 11, 2018

Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer.

Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer.

Journal: Cancer medicine

Published: January 04, 2018

PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS.

PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS.

Journal: Journal of medical genetics

Published: March 29, 2016

Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2.

Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2.

Journal: Human molecular genetics

Published: December 22, 2014

Showing 1-12 of 17

Last Updated: 09/26/2026